News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The company is positioning the blood-based test as an alternative to invasive chorionic villus sampling, the current standard in Denmark.
The company's test uses self-collected saliva samples from potential parents to assess their future child's genetic predisposition to various diseases.
The firm's revenue decrease was largely driven by a decline in testing volumes due to the COVID-19 pandemic, it said.
The deal covers SpeeDx's ResistancePlus and PlexPCR product lines, which include tests for sexually transmitted infections and antibiotic resistance.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
